Sven Streit1, Rosalinde K E Poortvliet2, Wendy P J den Elzen3, Jeanet W Blom2, Jacobijn Gussekloo4,5. 1. Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland. 2. Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands. 4. Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands J.Gussekloo@lumc.nl. 5. Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
PURPOSE: Hypertension trials often exclude patients with complex health problems and lack generalizability. We aimed to determine if systolic blood pressure (SBP) in patients undergoing antihypertensive treatment is associated with 1-year changes in cognitive/daily functioning or quality of life (QoL) in persons aged ≥75 years with or without complex health problems. METHODS: We analyzed data from a population-based prospective cohort study (Integrated Systematic Care for Older Persons [ISCOPE]) with a 1-year follow-up. Stratified by SBP level in the year before baseline, we used mixed-effects linear regression models to evaluate the change from baseline to 1-year follow-up in outcome measures (Mini-Mental State Examination [MMSE], Groningen Activity Restriction Scale [GARS], and EQ-5D-3L). We adjusted for age, sex, and baseline MMSE/GARS/EQ-5D-3L scores and stratified for complex health problems as a proxy for frailty. RESULTS: Participant (n = 1,266) age averaged 82.4 (SD 5) years, and 874 (69%) were women. For participants undergoing antihypertensive therapy (1,057; 83.5%) and with SBP <130 mm Hg, crude cognitive decline was 0.90 points MMSE, whereas in those with SBP >150 mm Hg, it was 0.14 points MMSE (ie, 0.76-point less decline; P for trend = .013). Complex health problems modified the association of SBP with cognition; the association was seen in those with antihypertensive treatment (P for trend <.001), not in those without (P for trend = .13). Daily functioning/QoL did not differ across the strata of SBP or antihypertensive treatment. CONCLUSIONS: Participants aged ≥75 years undergoing antihypertensive treatment, with SBP ≥130 mm Hg compared to <130 mm Hg, showed less cognitive decline after 1 year, without loss of daily functioning or QoL. This effect was strongest in participants with complex health problems. More studies should be conducted to determine if there is a causal relation and to understand the mechanism of the association observed.
PURPOSE:Hypertension trials often exclude patients with complex health problems and lack generalizability. We aimed to determine if systolic blood pressure (SBP) in patients undergoing antihypertensive treatment is associated with 1-year changes in cognitive/daily functioning or quality of life (QoL) in persons aged ≥75 years with or without complex health problems. METHODS: We analyzed data from a population-based prospective cohort study (Integrated Systematic Care for Older Persons [ISCOPE]) with a 1-year follow-up. Stratified by SBP level in the year before baseline, we used mixed-effects linear regression models to evaluate the change from baseline to 1-year follow-up in outcome measures (Mini-Mental State Examination [MMSE], Groningen Activity Restriction Scale [GARS], and EQ-5D-3L). We adjusted for age, sex, and baseline MMSE/GARS/EQ-5D-3L scores and stratified for complex health problems as a proxy for frailty. RESULTS:Participant (n = 1,266) age averaged 82.4 (SD 5) years, and 874 (69%) were women. For participants undergoing antihypertensive therapy (1,057; 83.5%) and with SBP <130 mm Hg, crude cognitive decline was 0.90 points MMSE, whereas in those with SBP >150 mm Hg, it was 0.14 points MMSE (ie, 0.76-point less decline; P for trend = .013). Complex health problems modified the association of SBP with cognition; the association was seen in those with antihypertensive treatment (P for trend <.001), not in those without (P for trend = .13). Daily functioning/QoL did not differ across the strata of SBP or antihypertensive treatment. CONCLUSIONS:Participants aged ≥75 years undergoing antihypertensive treatment, with SBP ≥130 mm Hg compared to <130 mm Hg, showed less cognitive decline after 1 year, without loss of daily functioning or QoL. This effect was strongest in participants with complex health problems. More studies should be conducted to determine if there is a causal relation and to understand the mechanism of the association observed.
Authors: M Kivipelto; E L Helkala; M P Laakso; T Hänninen; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen Journal: BMJ Date: 2001-06-16
Authors: Sripal Bangalore; Bora Toklu; Eugenia Gianos; Arthur Schwartzbard; Howard Weintraub; Gbenga Ogedegbe; Franz H Messerli Journal: Am J Med Date: 2017-01-19 Impact factor: 4.965
Authors: Yue-Bin Lv; Peng-Fei Zhu; Zhao-Xue Yin; Virginia Byers Kraus; Diane Threapleton; Choy-Lye Chei; Melanie Sereny Brasher; Juan Zhang; Han-Zhu Qian; Chen Mao; David Bruce Matchar; Jie-Si Luo; Yi Zeng; Xiao-Ming Shi Journal: J Am Med Dir Assoc Date: 2017-02-01 Impact factor: 4.669
Authors: Caterina Rosano; William T Longstreth; Robert Boudreau; Christopher A Taylor; Yan Du; Lewis H Kuller; Anne B Newman Journal: J Am Geriatr Soc Date: 2011-03 Impact factor: 5.562
Authors: Jeff D Williamson; Mark A Supiano; William B Applegate; Dan R Berlowitz; Ruth C Campbell; Glenn M Chertow; Larry J Fine; William E Haley; Amret T Hawfield; Joachim H Ix; Dalane W Kitzman; John B Kostis; Marie A Krousel-Wood; Lenore J Launer; Suzanne Oparil; Carlos J Rodriguez; Christianne L Roumie; Ronald I Shorr; Kaycee M Sink; Virginia G Wadley; Paul K Whelton; Jeffrey Whittle; Nancy F Woolard; Jackson T Wright; Nicholas M Pajewski Journal: JAMA Date: 2016-06-28 Impact factor: 56.272
Authors: Behnam Sabayan; Anna M Oleksik; Andrea B Maier; Mark A van Buchem; Rosalinde K E Poortvliet; Wouter de Ruijter; Jacobijn Gussekloo; Anton J M de Craen; Rudi G J Westendorp Journal: J Am Geriatr Soc Date: 2012-11-05 Impact factor: 5.562
Authors: Karen C Johnson; Karen L Margolis; Mark A Espeland; Christopher C Colenda; Howard Fillit; Joann E Manson; Kamal H Masaki; Charles P Mouton; Ronald Prineas; Jennifer G Robinson; Sylvia Wassertheil-Smoller Journal: J Am Geriatr Soc Date: 2008-07-15 Impact factor: 5.562
Authors: A Zarina Kraal; Hailey L Dotterer; Neika Sharifian; Emily P Morris; Ketlyne Sol; Afara B Zaheed; Jacqui Smith; Laura B Zahodne Journal: J Gerontol A Biol Sci Med Sci Date: 2021-07-13 Impact factor: 6.053
Authors: Sonal J Patil; Nuha K Wareg; Kelvin L Hodges; Jamie B Smith; Mark S Kaiser; Michael L LeFevre Journal: Ann Fam Med Date: 2020-01 Impact factor: 5.166
Authors: Jonathan M K Bogaerts; Rosalinde K E Poortvliet; Veerle M G T H van der Klei; Wilco P Achterberg; Jeanet W Blom; Ruth Teh; Marama Muru-Lanning; Ngaire Kerse; Anna Rolleston; Carol Jagger; Andrew Kingston; Louise Robinson; Yasumichi Arai; Ryo Shikimoto; Jacobijn Gussekloo Journal: J Hypertens Date: 2022-07-11 Impact factor: 4.776